191 related articles for article (PubMed ID: 30470972)
1. New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer.
Verdaguer H; Arroyo A; Macarulla T
Target Oncol; 2018 Dec; 13(6):691-704. PubMed ID: 30470972
[TBL] [Abstract][Full Text] [Related]
2. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
3. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Cinar P; Ko AH
Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
Rubinson DA; Wolpin BM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
[TBL] [Abstract][Full Text] [Related]
5. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
[TBL] [Abstract][Full Text] [Related]
7. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
8. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
9. Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?
Varadhachary GR; Wolff RA
J Oncol Pract; 2016 Sep; 12(9):797-805. PubMed ID: 27621332
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of pancreatic cancer. Actuality and perspective].
Bittoni A; Andrikou K; Lanese A; Santoni M; Pellei C; Faloppi L; Del Prete M; Giampieri R; Cascinu S
Recenti Prog Med; 2015 May; 106(5):208-16. PubMed ID: 25994537
[TBL] [Abstract][Full Text] [Related]
11. Second line treatment options for pancreatic cancer.
Passero FC; Saif MW
Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
[TBL] [Abstract][Full Text] [Related]
12. A review of systemic therapy for advanced pancreatic cancer.
El-Rayes BF; Philip PA
Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
[TBL] [Abstract][Full Text] [Related]
13. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
14. Taxanes: impact on pancreatic cancer.
Chiorean EG; Von Hoff DD
Anticancer Drugs; 2014 May; 25(5):584-92. PubMed ID: 24463484
[TBL] [Abstract][Full Text] [Related]
15. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
16. Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer.
Bien H; Mackenzie GG; Choi M
Recent Pat Anticancer Drug Discov; 2016; 11(4):376-383. PubMed ID: 27480831
[TBL] [Abstract][Full Text] [Related]
17. The winning formulation: the development of paclitaxel in pancreatic cancer.
Ma WW; Hidalgo M
Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
[TBL] [Abstract][Full Text] [Related]
18. Immune Therapy in Pancreatic Cancer: Now and the Future?
Zhang Y; Choi M
Rev Recent Clin Trials; 2015; 10(4):317-25. PubMed ID: 26374557
[TBL] [Abstract][Full Text] [Related]
19. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
20. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
